AstraZeneca PLCAZN:NYQ

29.03
0.01 / 0.03%
2.89m
15.17 %
0.7983
Latest price in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Feb 11 2016 18:55 GMT.

Summary

AstraZeneca PLC (AZN:NYQ) set a new 52-week low during Monday's trading session when it reached 28.29. Over this period, the share price is down 16.77 %.

52-week range
Today
28.29
Feb 08 2016
36.69
Apr 22 2015
Markit short selling activity
Low
Medium
High
Open29.50
Day high29.50
Day low28.96
Bid29.02
Offer29.03
Previous close29.04
Average volume7.51m
Shares outstanding2.53bn
Free float2.52bn
P/E (TTM)26.01
Market cap73.34bn USD
EPS (TTM)1.12 USD
Annual div (IAD)1.90 USD
Annual div yield (IAD)6.54%
Div ex-dateAug 12 2015
Div pay-dateSep 14 2015
Next div ex-dateFeb 17 2016
Next div pay-dateMar 21 2016
Data delayed at least 15 minutes, as of Feb 11 2016 18:55 GMT.

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
AstraZeneca PLC-4.73 %-7.96 %-13.16 %-15.17 %+19.79 %
S&P 500 INDEX-3.32 %-3.73 %-11.11 %-10.47 %+39.33 %
Data delayed at least 15 minutes, as of Feb 11 2016 18:55 GMT.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.